Arranon is a Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Nelarabine.
| Product ID | 0078-0683_3616a9ae-3037-42aa-825f-78628639e3e9 |
| NDC | 0078-0683 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Arranon |
| Generic Name | Nelarabine |
| Dosage Form | Injection |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 2016-10-05 |
| Marketing Category | NDA / NDA |
| Application Number | NDA021877 |
| Labeler Name | Novartis Pharmaceuticals Corporation |
| Substance Name | NELARABINE |
| Active Ingredient Strength | 5 mg/mL |
| Pharm Classes | Nucleoside Metabolic Inhibitor [EPC],Nucleic Acid Synthesis Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |
| Marketing Start Date | 2016-10-05 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA021877 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2016-10-05 |
| Marketing Category | NDA |
| Application Number | NDA021877 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2019-08-02 |
| Ingredient | Strength |
|---|---|
| NELARABINE | 5 mg/mL |
| SPL SET ID: | fffa5d75-0dba-4ad7-a252-5f60fa28489a |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0078-0683 | Arranon | nelarabine |
| 43598-142 | Nelarabine | Nelarabine |
| 70710-1726 | Nelarabine | Nelarabine |
| 70710-1839 | Nelarabine | Nelarabine |
| 70771-1685 | Nelarabine | Nelarabine |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() ARRANON 78325294 2901813 Live/Registered |
NOVARTIS PHARMA AG 2003-11-10 |
![]() ARRANON 78226967 2877259 Dead/Cancelled |
GLAXOSMITHKLINE LLC 2003-03-18 |